Search results
Showing 101 to 150 of 8100 results
This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Our board sets out our strategic priorities and policies.
The Patient Access Schemes Liaison Unit (PASLU) works with companies who are considering a patient access scheme for their drug or treatment. Patient
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
We want you to tell us what matters to you, your organisation or your community.
To help us understand the needs of our users we are offering the opportunity to be directly involved in the work we do. Fellows, registrars and...
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Digital technologies for managing non-specific low back pain: early value assessment (HTE16)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....
View recommendations for HTE16Show all sections
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
All our committees include experienced professionals with knowledge of a particular topic within health or social care . Professional members also...
Find out more about being on a committee at NICE.
A public consultation on our new approach to prioritising guidance is now open
Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
Achieving and demonstrating compliance with NICE TA and HST guidance
The NHS and patients need evidence that commissioners are funding medicines and treatments approved through the NICE Technology Appraisal (TA) or...
Support for industry to engage with NICE during all stages of health technology development
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
PDAs help people decide on healthcare options. They provide evidence-based information on the options available, along with likely outcomes, benefits,
Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing
Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.
View recommendations for IPG783Show all sections
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a role in...
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together...
NICE is trialling an innovative new approach to the way digital products, devices and diagnostics are assessed.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
The different types of health, public health and social care information provided by NICE.
NICE guidance that could generate cost savings.
Biosimilar technologies: NICE position statement - information for the public
Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...
NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...
There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...
Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...
On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar
Tools and resources to help you implement guidance and quality standards at work.
We work with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area,...
NICE transparency of spend
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
Role and responsibilities of the National Institute of Health and Care Excellence
NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.
Join Nice's Public Involvement Programme expert panel
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
NICE committee vacancies for health, social care and other professionals and practitioners
We're looking for health, social care and other professionals and practitioners to take an active role in producing a NICE guideline or quality standard.
NICE committee vacancies for patients, service users, carers and lay people
// Return to the our committees home page .
The resources in this section have been developed to help you deliver services to your users. Buy books, journals and databases Use the NICE...
The NICE Electronic and Print Content Framework Agreement - enables the NHS and other health and social care related organisations to buy medical and healthcare related content.